Alan is a Senior Advisor on the Frazier Life Sciences team with over 40 years of operational experience as an entrepreneur and chief executive.
Alan joined Frazier Healthcare Partners as a Venture Partner in 2007, and has been involved with multiple Life Sciences portfolio companies as a CEO and board member. He was the founding CEO of Incline Therapeutics (acquired by The Medicines Company), a Frazier portfolio company developing a novel drug-device combination for post-operative pain. He also previously served as President and CEO of Heartstream (acquired by Hewlett-Packard), a company that developed, manufactured, and marketed an innovative automatic external defibrillator that revolutionized the treatment of sudden cardiac arrest.
Prior to joining Frazier, Alan was the President and CEO of Northstar Neuroscience, a company developing innovative therapies for neurological diseases and disorders. Earlier, he was President of Heart Technology (acquired by Boston Scientific), a company that developed, manufactured, and marketed devices for removing plaque from coronary arteries. Before joining Heart Technology, Alan was Vice President of Research and New Business Development and a board member of the Ethicon division of Johnson & Johnson.
Alan is a member of the Board of Trustees of The Institute for Infectious Disease Research (f.k.a. Seattle Biomedical Research Institute), a not-for-profit institute conducting research on infectious diseases such as AIDS, malaria, and tuberculosis. He also serves on the boards of Intuitive Surgical (NASDAQ: ISRG), Proteus Digital Health, Chrono Therapeutics, and Abyrx (f.k.a. Orthocon).
Alan received his Ph.D. in Organic Chemistry from Purdue University and holds a B.S. in Chemistry from City University of New York. He was also awarded an Honorary Doctor of Science from Purdue.
City University of New York (B.S.)
Purdue University (Ph.D.)